三平剂使用对抗CGRP mAbs反应的影响:一项前性队列研究
Catello Vollono1,2, Marina Romozzi3,4, Antonio Munafò5
1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
Journal of neurology
|June 19, 2025
概括
使用三药的患者经历了抗CGRP单克隆抗体 (mAbs) 治疗偏头痛的更大效果. 这表明,在控制头痛频率方面,三类药物和抗CGRP mAbs之间存在潜在的协同作用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛治疗领域包括针对CGRP的单克隆抗体 (anti-CGRP mAbs).
- 患者曾使用过三类药物的病史可能会影响使用抗CGRP mAbs.的治疗结果.
研究的目的:
- 为了比较临床特征和治疗对抗CGRP mAbs的治疗反应,在有史以来使用三药的患者和非使用者之间进行了比较.
- 评估之前使用三胺对抗CGRP mAb治疗期间偏头痛频率和残疾的影响.
主要方法:
- 对336名门诊患者进行前性队列研究,这些患者接受了12个月的抗CGRP mAbs.
- 收集的数据包括每月头痛日 (MHD),止痛药的使用,HIT-6和MIDAS分数.
- 习惯性使用者 (TRIPTANS组) 和非当前使用者 (NO-TRIPTANS组) 之间的结果比较.
主要成果:
- 没有卜素的组比卜素组的基线MHDs更高.
- 在整个治疗过程中,TRIPTANS组表现出明显较低和持续的MHDs.
- 在第1个和第12个月的TRIPTANS组中观察到更高的响应率 (MHD≥50%的减少).
结论:
- 习惯性使用平坦的患者表现出抗CGRP mAbs.的增强疗效.
- 在偏头痛管理中,三类药物和抗CGRP mAbs之间的共同或协同机制的潜力.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
418
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
418
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
267
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
267
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
603
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
603
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
644
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
644


